Nasal deposition of ciclesonide nasal aerosol and mometasone aqueous nasal spray in allergic rhinitis patients

American Journal of Rhinology and Allergy

Volumn 28, Issue 2, 2014, Pages 117-121

  Emanuel, Ivor A ^a   Blaiss, Michael S ^b   Meltzer, Eli O ^c   Evans, Philip ^d   Connor, Alyson ^d  

^a San Francisco Office   (United States)

^b Allergy and Asthma Care   (United States)

^c ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^d Quotient Clinical Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; MOMETASONE FUROATE; NOSE SPRAY; TECHNETIUM 99M; ANTIALLERGIC AGENT; PREGNANE DERIVATIVE;

ADULT; AEROSOL; APHTHOUS STOMATITIS; ARTICLE; CLINICAL ARTICLE; COLLIMATOR; CROSSOVER PROCEDURE; DRUG RETENTION; DYSMENORRHEA; FEMALE; GAMMA CAMERA; GAMMA SCINTIGRAPHY; HAY FEVER; HEADACHE; HUMAN; ISOTOPE LABELING; MALE; METERED DOSE INHALER; NASOPHARYNX; NOSE; NOSE CAVITY; OPEN STUDY; PERENNIAL RHINITIS; RADIOACTIVITY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSPENSION; ADOLESCENT; AGED; COMPARATIVE STUDY; DRUG EFFECTS; MIDDLE AGED; RHINITIS, ALLERGIC; SCINTISCANNING; SENSORY FEEDBACK; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; FEEDBACK, SENSORY; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PREGNADIENEDIOLS; PREGNENEDIONES; RADIONUCLIDE IMAGING; RHINITIS, ALLERGIC; YOUNG ADULT;

EID: 84897143461     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2014.28.4026     Document Type: Article

References (23)

1. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 124:S43-S70, 2009.
2. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108:S2-S8, 2001.
3. Blaiss MS, Meltzer EO, Derebery MJ, and Boyle JM. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc 28:S4-S10, 2007.
4. Meltzer EO, and Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106:S12-S16, 2011.
5. Bousquet J, Van Cauwenberge P, and Khaltaev N, ARIA Workshop Group; World Health Organization. Allergic Rhinitis and Its Impact on Asthma (ARIA). J Allergy Clin Immunol 108:S147-S334, 2001.
6. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008. (Pubitemid 352033573)
7. Luskin AT, Blaiss MS, Farrar JR, et al. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: A white paper. Allergy Asthma Proc 32:168-177, 2011.
8. Velders GJ, Andersen SO, Daniel JS, et al. The importance of the Montreal Protocol in protecting climate. Proc Natl Acad Sci U S A 104:4814-4819, 2007. (Pubitemid 47186133)
9. Nave R, and McCracken N. Metabolism of ciclesonide in the upper and lower airways: Review of available data. J Asthma Allergy 1:11-18, 2008.
10. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochemical Pharmacol 73:1657-1664, 2007. (Pubitemid 46527549)
11. Sunovion Pharmaceuticals, Inc. Omnaris (ciclesonide) nasal spray package insert. Marlborough, MA; October 2011.
12. Sunovion Pharmaceuticals, Inc. Zetonna (ciclesonide) nasal aerosol package insert. Marlborough, MA; January 2012.
13. Mahadevia PJ, Shah S, Leibman C, et al. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: A conjoint analysis. Ann Allergy Asthma Immunol 93:345-350, 2004. (Pubitemid 39382975)
14. Bunntag C, Suprihati D, and Wang D. Patient preference and sensory perception of three intranasal corticosteroids for allergic rhinitis. Clin Drug Invest 23:39-44, 2003. (Pubitemid 36143336)
15. Berger WE, Prenner B, Turner R and Meltzer EO. A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoate aqueous nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc 34:542-550, 2013.
16. Sher ER and Ross JA. Intranasal corticosteroids: The role of patient preference and satisfaction. Allergy Asthma Proc 35:24-33, 2014.
17. The National Allergy Survey Assessing Limitations (NASAL): Materials and respondent characteristics. J Fam Pract 61(suppl):S29-S33, 2012.
18. Health and Safety Executive. Work with ionising radiation: Ionising Radiation Regulations 1999. Sudbury, Suffolk, UK: HSE Books, 2000.
19. Pitcairn GR, and Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 10:187-198, 1997. (Pubitemid 27415413)
20. Kublik H and Vidgren MT. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 29:157-177, 1998. (Pubitemid 28044092)
21. Newman SP, Morén PF, and Clarke SW. The nasal distribution of metered dose inhalers. J Larnygol Otol 101:127-132, 1987. (Pubitemid 17009562)
22. Newman SP, Morén F, and Clarke SW. Deposition pattern from a nasal pump spray. Rhinology 25:77-82, 1987. (Pubitemid 17090277)
23. Newman SP, Morén F, and Clarke SW. Deposition pattern of nasal sprays in man. Rhinology 26:111-120, 1988.